

(19) World Intellectual Property Organization International Bureau



556931

(43) International Publication Date
9 December 2004 (09.12.2004)

PCT

(10) International Publication Number
WO 2004/106346 A1

(51) International Patent Classification⁷: **C07D 498/04**, 491/04, A61K 31/5383, 31/436, 31/4355, A61P 25/18 // (C07D 498/04, 265:00, 221:00) (C07D 491/04, 319:00, 221:00), 491/04

(74) Common Representative: JANSSEN PHARMACEUTICA N.V.; Turnhoutseweg 30, B-2340 Beerse (BE).

(21) International Application Number:
PCT/EP2004/050922

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 26 May 2004 (26.05.2004)

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(25) Filing Language: English

Published:

(26) Publication Language: English

— with international search report

(30) Priority Data:
PCT/EP03/05789 30 May 2003 (30.05.2003) EP

(71) Applicant (*for all designated States except US*): JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).


For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): BARTOLOMÉ NEBREDA, José, Manuel [ES/ES]; c/o Janssen Cilag S.A., Edificio Johnson & Johnson, Paseo de las Doce Estrellas 5-7, Campo de las Naciones, E-28042 Madrid (ES). ANDRÉS-GIL, José, Ignacio [ES/ES]; c/o Janssen Cilag S.A., Edificio Johnson & Johnson, Paseo de las Doce Estrellas 5-7, Campo de las Naciones, E-28042 Madrid (ES).

WO 2004/106346 A1

(54) Title: INDOLE DERIVATIVES WITH AN IMPROVED ANTIPSYCHOTIC ACTIVITY



(57) **Abstract:** The present invention relates to a novel indol derivative according to Formula (I), a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof, an N-oxide form thereof or a quaternary ammonium salt thereof, wherein the variables R¹, R², R³, R⁴, R⁵, p, a¹=a²=a³=a⁴, Z¹-Z², X and Y are defined as in claim 1. Said derivative exhibit a binding affinity towards dopamine receptors, in particular towards dopamine D₂, D₃ and D₄ receptors, with selective serotonin reuptake inhibition properties and acting as 5-HT_{1A} agonists or partial agonists. The invention also relates to pharmaceutical compositions comprising the compounds according to the invention, the use thereof for the prevention and/or treatment of a range of psychiatric and neurological disorders, in particular certain psychotic disorders, most in particular schizophrenia and processes for their production.